25
November 2020 Enhancing Lives with Trappsol ® Cyclo™ for NPC and Neurodegenerative Diseases Non-Confidential Presentation
November 2020
Enhancing Lives with Trappsol® Cyclo™ for NPC and
Neurodegenerative Diseases
Non-Confidential Presentation
Some of the information in this presentation relates to future events or future business and financial performance. Such statements constitute forward-looking
information within the meaning of the Private Securities Litigation Act of 1995. Such statements can be only predictions and the actual events or results may
differ from those discussed due to, among other things, the risks described in the public filings and other publications of Cyclo Therapeutics, Inc. Forward-
looking statements are identified by words such as “anticipates”, “projects”, “expects”, “plans”, “intends”, “believes”, “estimates”, “target”, and other similar
expressions that indicate trends and future events.
The market data and certain other statistical information used throughout this presentation are based on independent industry publications, governmental
publications, reports by market research firms or other independent sources. Some data are also based on the Company’s good faith estimates. In addition,
this presentation includes summaries of scientific activities and outcomes that have been condensed to aid the reader in gaining general understanding.
The information about Cyclo Therapeutics, Inc. and its subsidiaries is solely for information purposes and is not to be construed as an offer to sell or the
solicitation of an offer to buy any security in any state.
Factors that could cause the Company’s results to differ materially from those expressed in forward looking statements include, without limitation, the
Company’s need for additional capital; the Company’s reliance on its Trappsol® Cyclo™ product, which may never receive regulatory approval; the
Company’s ability to commercialize any of its proposed drug products if it receives regulatory approval; the outcome of the Company’s clinical trials, which
may not support the Company’s product claims or may result in adverse side effects; the cost and timing of the Company’s clinical trials; the Company’s
reliance on third parties to conduct clinical trials and to produce its products; and other risks associated with being a clinical stage biotechnology company.
This presentation is not to be copied, transmitted, displayed, distributed (for compensation or otherwise), or altered in any way without the prior written
consent of Cyclo Therapeutics, Inc.
2
Safe Harbor Statement
Innovative and Strong
1
2
4
3
5
7
6
8
P3 Ready Lead Asset with Potential to Address
Diseases Beyond Niemann Pick Type C
Orphan Drug Market Exclusivity & IP
Regulatory Accomplishments & Future
Milestones
Successful P1/2 Controlled Clinical Data
Addressable Market Penetrable by Modestly
Sized Salesforce
Priority Review Voucher Opportunity
Multiple Paths to Value Creation
Seasoned Leadership & Advisory Team
Highlights
3
Company Overview & History
4
1990 2006 2009 2015 2017 2019 2020+
Founded as a cyclodextrin-
distribution company
headquartered out of Gainesville, FL
Cyclo Therapeutics
transformed into a
company with its
primary focus on
drug development
Dr. Benny Liu shows that one version of cyclodextrins,
hydroxypropyl beta cyclodextrins, can release
cholesterol from cells in animal models of Niemann-Pick
Disease Type C (NPC)
Company began providing cyclodextrins to
NPC families for use in compassionate
programs in the US, Brazil and other countries
Used data from
compassionate
programs in NPC to
launch the first
clinical trials for the
NPC1 indication
First patients
enrolled and
dosed in Phase
I and Phase I/II
trials
Announces positive
Phase I top-line
results and interim
analysis of Phase I/II
Phase III readyNote: Reference slide 14 for
Phase III Design and
Regulatory Strategy
2000
(1) As of 07/22/2020
$26,500,000 invested since 2014
2014
1. First Patient In (FPI) for Phase III
(Study 301)
2. Top Line results for completed
Phase I/II (Study 201)
3. Commercial Scale Manufacturing
Batch runs
4. Pre-IND Meeting Request for AD
program
Milestones
5
May
2020
August
2020
October
2020
1Q
2021
Positive Phase I (Study
101) Trial Top Line Results
and Phase I/II (Study 201)
Trial Interim Analysis
EMA/PDCO Summary Report
on Paediatric Investigation
Plan for Phase III (Study 301)
Final Report on 18-month Expanded
Access Program in Alzheimer's Disease
June
2020
Submission of 60-month
expiration date at controlled
room temperature and 96-hour
In-Use stability completed
September
2020
1. Reported positive efficacy data on an additional 3 patients
who completed the 48-week Phase I/II (Study 201)
2. Final Clinical Study Report (CSR) on Phase I (Study 101)
submitted to FDA
Confirmation from FDA that
Phase III (Study 301) Global
Pivotal Trial can begin
enrollment
December
2020
Led and Supported by Highly Experienced Team
Management Team
Jeffrey L. Tate, PhDCOO, CQO, Director
Sharon H. Hrynkow, PhDChief Scientific Officer &
SVP Medical Affairs
N. Scott FineCEO & Director
Joshua M. FineChief Financial Officer
Michael LisjakChief Regulatory Officer &
SVP for Business Development
6
• Identified several companies through career that have grown in revenue
and valuations, including Green Mountain Coffee Roasters, now Keurig.
• Served as Chairman of the Global Virus Network, a leading global think
tank sponsoring global health programs with some of the world’s leading
Virologists.
• 35+ years in regulated manufacturing, CMC and quality for
biopharmaceutical products
• 20+ years in biopharmaceutical start-up companies
• Neuroscientist with more than 25 years' experience in global health
arena, public and private sectors.
• Senior executive at NIH.
• First president of non-profit Global Virus Network.
• Member of President's Council of Advisors on Science and Technology.
• 5 years at Cyclo Therapeutics leading clinical and scientific programs.
20+ years of regulatory expertise in drug development for multiple
therapeutic areas including rare disease
o Director level global roles within Sanofi, Pfizer and Accenture
Ensured optimal global/regional Health Authority interactions
Regulatory strategy for 15+ business development opportunities
Broad expertise in healthcare finance, operations and banking.
o Completed partnerships with Roche, Sanofi, and the Cystic
Fibrosis Foundation
History of creating shareholder value.
o Recently part of Senior management team at Icagen, Inc. which
successfully ran M&A process ending in a transaction with Ligand.
NPC Market Overview
Existing NPC Cases Number of live births Incidence New Cases / YearAnnual IV Orphan
Drug Price (Avg.)
Total Addressable
Market
3,000(1) 137,000,000 1/100,000(2) 1,370 $404,737(3) ~$550 million
(1) Extrapolation from BMC Neurol. Dec 15,15(1):257) and other assumptions
(2) Wassif, C et al. Genet Med. 2016 January ; 18 (1):41-48
(3) LifeSci Capital., “Analysis of Orphan Drug Market”. Feb 4, 2016
Niemann-Pick Disease Type C represent a significant market opportunity
Diagnosis capacity is improving – numbers of patients
seeking treatment will increase
Only current treatment option is Miglustat in the EU only,
which does not provide any systemic benefit
Adult forms of NPC increasingly diagnosedNPC is characterized by progressive worsening of symptoms, resulting in
patients seeking solutions for marginal quality of life improvements
7
Limited human & financial resources required in order to achieve market
penetration
Distribution Channel already in place through Cyclo’s expanded access
program
Deep relationships on the part of scientific advisory board pave way for pivotal trial enrollment and eventual commercialization upon approval
NPC Treatment Differentiating Factors
Company Product / Route: Descriptor Potential Indication
Trappsol® Cyclo™
(Intravenous every 2 weeks, Home infusions)
Met all primary endpoints of the Phase I and
Phase I/II interim analysis showing favorable
safety and efficacy. Phase III ready asset, first
patient in planned 1Q ‘21.
Systemic and Neurological
Zavesca*
(Oral 3 times daily)
EU and other international countries approved.
Off-label in US, not reimbursed.Neurological
Arimoclomol (Oral 3 times daily)
Projected US approval March ’21. EU
submission H2 ’20. Phase II/III data met
primary endpoints in two-sub-groups, but was
not statistically significant overall, co-primary
failed.
Neurological
IB1001 (Oral 3 times daily)
Estimated study report Phase I by
Q4’20. Phase II, 1-year study, initiated
Neurological
* Only approved Treatment (non-US)
8
Stimulates the release of cholesterol from cells resulting in encouraging efficacy for all dose groups as well as pharmacodynamic effects in cholesterol homeostasis across all dose groups
Recent data show the drug engages with its targets and crosses the blood-brain-barrier as well as enters the Central Nervous System and spinal fluid
Granted Orphan Drug Designation (ODD) by FDA and EMA
Rare Pediatric Disease Designation (US) and Fast Track Designation (US)
Trappsol® Cyclo™
Profile
Potential platform technology for other neurodegenerative diseases, including Alzheimer’s Disease
Patent Application for treatment of Alzheimer's Disease, if granted, could provide patent protection until 2039
Trade secrets around the formulation and manufacturing of the drug product
Market exclusivity for NPC is 7 years in US and 10 to 12 years in EU
Cyclodextrin
Portfolio & IP
Target Product Profile differentiates against competition to treat the systemic and neurologic manifestations of NPC
Favorable safety profile in all clinical trials and all dose groups to date.
6 of 7 patients that completed the PII study improved by at least 1 point in 2 domains of the 17-domain NPC Severity Scale(1), meeting the first efficacy outcome measure
Individual patients report feeling more energetic, more focused, and families report greater participation of the patients in social situations
Differentiated
product
candidate with
potential market
approval in 2023
Commercial
3,000 estimated NPC cases worldwide(2)
We estimate a $550mm+ annual addressable market based on average annual IV orphan drug price
Company has shown manufacturing scalability for commercial use
9
(1) With no drug interventions, patients would be expected to worsen by 1.5 points
(2) Extrapolation from BMC Neurol. Dec 15,15(1):257) and other assumptions
Trappsol® Cyclo™ Profile Creates Significant
Opportunity
Modifying natural chemistry to restore human physiology.
Niemann-Pick Disease Type C (NPC) is a rare genetic disease. A defect in
the NPC1 protein causes cholesterol to accumulate in cells of major
organs, including liver and spleen, and in the brain. This in turn leads to
cell and tissue dysfunction and disease.
Trappsol® Cyclo™, our proprietary formulation of hydroxypropyl beta
cyclodextrin, has an affinity for cholesterol.
Significant body of in vitro work showing beta cyclodextrins remove cholesterol
from NPC cells.
Animal studies suggest that hydroxypropyl beta cyclodextrin can function like
the NPC1 protein, allowing cholesterol to be moved normally through cells
Cyclo Therapeutics’ clinical trials show that Trappsol ® Cyclo™ releases
cholesterol from cells and normalizes cholesterol metabolism, essentially
confirming data from in vitro and animal studies.`
Figure is courtesy of David Begley, Kings College
This schematic represents the affinity of
Cyclodextrins (cylinder) and cholesterol (red)
Trappsol® Cyclo™ Mechanism of Action in NPC
10
CyclodextrinCholesterol
Efficacy Outcome Measure 1: At least a one-point reduction (or improvement) in two or more of the 17-Domain NPC Clinical Severity Scale (NPC
CSS) measures
─ 6 of 7 patients met this endpoint (86% of those who completed)
─ Improvements seen in Swallow, Ambulation, Ability to Manage Seizures, Saccadic Eye Movements, Fine Motor Skills, Cognition. Individual
patient profiles differed, i.e. patients improved differently
Patients not receiving any intervention beyond Standard of Care would be expected to worsen in total score by 1.5 points over one year
Efficacy Outcome Measure 2: Change from baseline in Global Impression of Disease severity at 48 weeks
─ Using the Clinician’s Global Impression of Improvement scale, 5 of 7 patients who completed the trial improved, the other 2 patients stabilized.
5 of 7 improved in at least one of these features: walking, speaking, swallowing, fine motor and cognition. These 5 features are determined by NPC patients and their caregivers to be the most important for quality of life. A composite in Improvement in these five features is the primary outcome measure for the global pivotal trial
11
Tool developed by NIH to measure clinical signs and symptoms in:
9 major domains – ambulation, cognition, eye movement, fine motor, hearing, memory, seizures, speech, swallowing
─ Major domains are scored 0 - 5, with 0 as no disability
8 minor domains – auditory brainstem response, behavior, gelastic cataplexy, hyperreflexia, incontinence, narcolepsy, psychiatric, respiratory problems
─ Minor domains add points for severity of condition up to 2 additional points per domain
(1) Yanjanin, N et al. , AM J Med Genet B Neuropyshiatr Genet 2010, 153B: 132-140.
Phase I/II Interim Analysis Demonstrates Positive Efficacy
Outcomes
NPC Severity Scale(1)
Phase I/II data available to support moving to Global Phase III Pivotal Trial
NPC Phase I/II Interim Data - Summary
12
As a group, first seven patients to complete the Phase II trial meet
both efficacy outcome measures for the study
48 week trial, 24 doses
Individual patients showed improvements in all dose groups
Demonstrated a highly favorable safety profile
Trappsol® Cyclo™ crosses the blood brain barrier
Successive administration of Trappsol® Cyclo™ decreases Tau
levels, suggesting neuroprotective benefit
Improves neurological features of disease, including ataxia, and
quality of life for patients
2000 mg/kg dose selected for Phase III study
Completed Health Authority Meetings
Feb 2020 – F2F Type C Meeting was held with the Food and Drug Administration
May 2020 – Scientific Advice was received from the European Medicines Agency
Key outcomes from agencies included:
• Agreed with overall study design and no need for additional dose ranging studies (2,000 mg/kg selected)
• Agreed with strategy for selection of endpoints (primary, secondary and exploratory)
• Agreed with Statistical Analysis Plan design, inclusive of multiple interim analyses
• The Committee for Orphan Medicinal Products agreed that the currently proposed clinical development is
sufficient to demonstrate significant benefit
First Patient In
(FPI)
48 wk Interim
Analysis (IA)
File MAAs to
FDA and EMA
on 48wk CSR
US and EU
Approvals from
48 wk Interim
Analysis
Phase III Design and Regulatory Strategy
96 wk Study
Completion
File MAAs to
FDA and EMA
on 96 wk CSR
US and EU
Approvals from
96 wk Interim
Analysis
Ongoing Health Authority Discussions
Type C Written Response Only – Received confirmation
from FDA in October 2020 that Phase III (Study 301)
can begin enrollment
Pediatric Investigational Plan submitted 2Q 2020; Day
60 Feedback received 3Q 2020
Next Steps For Second Half of 2020
Finalize PIP Requirements, 4Q 2020
Clinical Trial Applications, 4Q 2020
13
Oct 2020 Jan 2021 Jun2021 Dec 2022Jun 2022 Jun 2023Mar 2023 Dec 2023 Mar 2024 Dec 2024
IND and CTA
Submissions
Last Patient in
(LPI)
Final Clinical
Study Report
Phase I results support moving directly into Phase III study
NPC Phase I Data - Summary
14
7 dose, 14-week trial with Phase I data confirmed a favorable safety profile,
consistent with our 10+ years of compassionate use data
Liver biopsies and biochemical data on cholesterol homeostasis show that
Trappsol® Cyclo™ removes trapped cholesterol from cells and impacts
cholesterol homeostasis
Tau decreased after seven doses in a majority of patients, suggesting that IV
administration of Trappsol® Cyclo™ is preventing neurodegeneration in NPC
patients
Efficacy signals from Trappsol® Cyclo™ include neurological improvements,
higher energy, and greater focus exhibited by the patient
All eligible patients wanted to continue on the drug in the extension protocol,
suggesting that they perceive benefit. In US, those on Extension protocol
receive drug through Home Infusions.
Trappsol® Cyclo™ Removes Cholesterol from Liver Cells
Baseline 14 Weeks
Cholesterol as measured by Filipin staining at
baseline and after 7 doses over 14 weeks
The lack of light blue represents the clearing
of cholesterol from cells15
Patient Reduction in Filipin Staining
1500 mg/kg
(6 patients)
2500 mg/kg
(4 patients)
1500 mg/kg(Mild)
2500 mg/kg
(Marked)
2500 mg/kg
(Marked)
Minimal
Mild
Moderate
Marked
In NPC patients, cholesterol accumulates abnormally in cells: this can be visualized
directly in liver cells through liver biopsies and a special stain for cholesterol
Cyclodextrin can function like the NPC1 protein, allowing cholesterol to be moved
normally through cells
Both 1500 mg/kg and 2500 mg/kg dose demonstrated that Trappsol® Cyclo™ clears
cholesterol from peripheral organs
Management believes this is evidence of a pathway to treat the systemic and
neurologic manifestations of the disease
.
Trappsol® Cyclo™ Reduces Tau, a Brain Protein
Associated with Neurodegeneration
16
Baseline Week 12
Visit
0
1000
2000
3000
Bio
mark
ers
of
NP
C in
CS
FSubjid=001-13
Subjid=001-12
Subjid=001-11
Subjid=001-10
Subjid=001-09
Subjid=001-08
Subjid=001-07
Subjid=001-06
Subjid=001-05
Subjid=001-04
Subjid=001-03
Subjid=001-02
Subjid=001-01
Tau (ng/L)
Biomarkers of NPC in CSF Following the 7th Dose by Subject and Time
In the majority of patients with high Tau levels, the
reduction is significant after seven doses
Tau is a protein found in cerebrospinal fluid (CSF)
that is elevated in neurodegenerative diseases
like Alzheimer's Disease, Parkinson’s, and NPC
Data from our ongoing studies demonstrated a
reduction in Tau levels.
Phase I Data (chart)
Tau levels as measured in the CSF are shown
here for 10 NPC patients who had lumbar
punctures prior to treatment with Trappsol®
Cyclo™ and after seven doses over a 14-week
period in the Phase I study
6 of 10 patients showed a reduction in Tau levels,
two remained stable, and two increased
Phase I/II Data (not shown)
Data from 3 patients in the Phase II study show
similar pattern at 24 weeks and 48 weeks.
Compassionate Use / Expanded Access with Intravenous
Trappsol® Cyclo™ Forms Foundation of Clinical Trials
Given no therapies for NPC, expanded access program began in 2009 with US and Brazilian patients being the first to use Trappsol®
Cyclo™ intravenously, later intrathecal added in some cases
─ Physicians in Europe later joined the program
─ Some patients now nearing the 10 year mark
Gathered safety and efficacy data from 20 NPC patients in 2014 – 2015 and used these data to launch formal clinical trials for
Trappsol® Cyclo™
Favorable safety profile allowed physicians to continue to use the drug for many years; individual patients benefited by reduction in liver
size; restoration of language skills; resolution of interstitial lung disease; improvement in fine and gross motor skills,
improvement in quality of life
Based on these findings, Cyclo Therapeutics published in October 2019 a set of case studies on expanded access use of HPβCDs to
treat NPC children and young adults
─ No safety issues, drug was well-tolerated, easy to administer
─ Moderately affected NPC patients treated with HPβCD showed slowing of disease progression
─ “Neurologic and neurocognitive benefits were seen in most patients with IV alone, independent of the addition of IT administration,”
Report found here(1)
17
(1) Hastings C, Vieira C, Liu B, et al. Expanded access with intravenous hydroxypropyl-β-cyclodextrin to treat children and young
adults with Niemann-Pick disease type C1: a case report analysis. Orphanet J Rare Dis. 2019;14(1):228. Published 2019 Oct 21.
Cognitive decline
Tau is a protein found in cerebrospinal fluid (CSF) that is elevated in neurodegenerative diseases like Alzheimer's Disease, Parkinson’s, and NPC
Data from our ongoing studies demonstrated a reduction in Tau levels (slide 17)
Cellular cholesterol increases the association of an enzyme, secretase, with the precursor protein to amyloid beta (APP), leading to increased levels of
amyloid beta
18
Background of Alzheimer’s Disease Program
Reference: J. Yao, et al. Neuroprotection by cyclodextrin in cell and mouse models of Alzheimer disease. J. Exp. Med. 2012, V. 209 (13): 2501-2513
NPC and Alzheimer’s Disease Share Common Features
Individual IND authorized by FDA to use Trappsol® Cyclo™ in late-onset Alzheimer’s patient, first geriatric patient
─ Intravenous Dosing of Alzheimer’s patient on a monthly basis began in 2018
PI is award-winning, highly recognized Alzheimer’s expert, Diana Kerwin, MD
Program costs funded 100% by external organization with Cyclo providing clinical materials, validation methodologies for biomarker analyses, and expert input on protocol design
FDA accepted annual report in 2019 which described favorable safety profile, stabilization of disease and improvements in behavior
After 18 months the patient voluntarily withdrew, not for safety reasons
Alzheimer’s Disease Compassionate Use Program
Treating Physician:
─ “The patient has shown cognitive and neurologic stability in serial
examinations during this study that indicates possible benefit as there would
be an expected measurable cognitive and functional decline over a 18-month
period in persons with Alzheimer’s disease dementia”
Family:
─ “Family reports short term memory loss without significant decline from
baseline during the 18-month study period”
Trappsol® Cyclo™ for Alzheimer’s Disease
Positive Results with Alzheimer Patient
Cell and Animal studies using HPβCDs for Alzheimer’s in Dr. Flint
Beal’s lab (Cornell) show(2):
HPβCDs added to cells that over-express the precursor protein
APP lowers amyloid beta
HPβCDs given subcutaneously to a mouse that over-expresses
APP:
─ Reduces amyloid beta by reducing cleavage of APP;
─ Improves memory as shown in a standard water maze test;
─ Reduces microgliosis;
─ Up-regulates proteins (e.g. NPC1) involved in cholesterol
transport and amyloid beta clearance
Compassionate use in a single late-onset Alzheimer’s
patient: After 18 months of monthly intravenous infusions, the
patient’s disease did not progress as measured with standard
cognitive tools. The patient and family reported less volatility
and greater word-finding ability. The safety profile was
favorable
Reduction of Amyloid Beta and Tau(1)
19
Alzheimer’s Mini-Mental State Evaluation Performance(3)
(1) Evidence of Trappsol® Cyclo™’s decreasing Tau levels has been shown in the Phase I and II trials
(2) Yao, J et al. J Exp Med 2012 (209): 2501-2513
(3) Patients with late-onset Alzheimer’s disease can be expected to decline 2 points in the MMSE per year
Baseline
20
22
24
26
28
30
32
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
MMSE
Month
Cyclo Patient Expected decline in patient with late onset Alzheimer's Disease Cognitively Normal = 30
Alzheimer’s Disease Clinical Outlook
20
Worldwide Clinical Trials selected to lead development and execution of our AD program
Clinical Plan
Protocol Synopsis in draft
─ Includes a dosing paradigm similar to the Compassionate Use program
─ Proposed strategy is to present a Phase II dose selection study
Pre-IND meeting request with FDA, first half 2021
Alzheimer’s Proposed Clinical Plan Highlights of Alzheimer’s Clinical Trial
Led and Supported by Highly Experienced Team
Board of Directors
Markus W. SiegerChairman
President & CEO of Polpharma Group
Independent Director
C.E. “Rick” StrattanFounder, Former Director of Marketing &
Business Development of Pharmatec
Independent Director
N. Scott FineCEO & Executive Director
Jeffrey L. Tate, PhDCOO, CQO & Executive Director
F. Patrick OstronicVice Chairman
Officer of US Pharmacia International &
CFO of The USP Group
Independent Director
William S. ShanahanFormer President & COO of Colgate-
Palmolive
Independent Director
Randall M. Toig, M.D.Associate Professor at Northwestern
University, Northwestern Memorial Hospital
OBGYN Surgeon & Serial Entrepreneur
Independent Director
21
Executive Summary
Cyclo Therapeutics is a clinical stage biotechnology company developing a cyclodextrin platform for the
treatment of Neurodegenerative Diseases
Excellent Recent Clinical Results from Phase I and Phase I/II Trials
Highly favorable safety profile in all trials and all dose groups
22
Lead candidate, Trappsol®
Cyclo™ is Phase III ready asset for NPC
Pipeline expansion in neurodegenerative diseases (Alzheimer's Disease)
Trappsol® Cyclo™ positioned to become the best-in-class, first line treatment for NPC
Releases cholesterol from cells, resulting in clinical improvements in NPC patients
Met all safety and efficacy endpoints in the PI (completed) and PII (ongoing, Interim data)
Granted Orphan Drug Designation (FDA and EMA) and Rare Pediatric Disease Designation (US) and Fast-Track Designation (US)
Trappsol® Cyclo™ improves quality of life for patients suffering from NPC
6 out of 7 patients who completed the 48-week Phase I/II trial met 1st efficacy outcome criterion
Crosses the blood-brain-barrier and reduces Tau, a biomarker for central nervous system neurodegeneration
Compound could have a preventative effect in overall symptom development1
Differentiated against competition to treat the systemic and neurologic manifestations of NPC
Late onset Alzheimer's disease progression was stabilized in Compassionate use program
1EMA/PDCO Summary Report 002839-PIP01-20
Appendix
Scientific Advisory Board
24
Scientific Advisory Board
Benny Liu, MDBoard Member
Rita Colwell, PhDCo-Chair
Caroline Hastings, MDBoard Member
Sharon H. Hrynkow, PhDCo-Chair
M. Flint Beal, MDBoard Member
• Internationally recognized scientist, microbiologist and founder of
CosmosID, a privately held bioinformatics firm.
• Distinguished University Professor at U. Maryland and Johns Hopkins
University. Former Director, National Science Foundation (1998 -
2006).
• National Medal of Science awardee. Member, US National Academy of
Sciences.
• Pediatric hematologist oncologist, Director of NeuroOncology, and
Professor of Pediatrics, UCSF Benioff Children's Hospital Oakland.
• First physician in US to use cyclodextrins for treatment in NPC,
compassionate use.
• Advisor to US and Australian NPC Advocacy organizations and to
physicians globally on NPC.
• Gastroenterologist at Alameda Healthy System, CA and Highland
Hospital. Globally recognized expert in lipid metabolism.
• First to discover that cyclodextrins release cholesterol from cells using
an animal model.
• Assistant Clinical Professor, UCSF.
• Internationally recognized authority on neurodegenerative
diseases. University Professor, Weill Cornell Medical College.
• Leads a highly productive research laboratory focused on Alzheimer's
Disease, Huntington's Disease, and ALS and published seminal
manuscript on use of cyclodextrins to improve memory in an animal
model of Alzheimer's Disease.
• Member, National Academy of Medicine.
• Neuroscientist with more than 25 years' experience in global health
arena, public and private sectors.
• Senior executive at NIH.
• First president of non-profit Global Virus Network.
• Member of President's Council of Advisors on Science and Technology.
• 5 years at Cyclo Therapeutics leading clinical and scientific programs.
Cyclo Therapeutics, Inc.6714 NW 16th Street, Suite BGainesville, FL 32653www.cyclotherapeutics.com
